SCHEMBL10276941

SCHEMBL10276941

O=C(O)CCCCCCCCCCc1ccc(Oc2ccccc2)cc1

nearest known ligand 0.75

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FFAR1 O14842 9/20 0.75
MAPT P10636 1/20 0.71
RXFP1 Q9HBX9 1/20 0.71
SRD5A2 P31213 1/20 0.65
FFAR4 Q5NUL3 5/20 0.63
HDAC3 O15379 1/20 0.59
MAPK1 P28482 1/20 0.59
ADRA1A P35348 1/20 0.59
HDAC4 P56524 1/20 0.59
SLC6A3 Q01959 1/20 0.59
HDAC1 Q13547 1/20 0.59
SMN1; SMN2 Q16637 1/20 0.59
HDAC7 Q8WUI4 1/20 0.59
HDAC2 Q92769 1/20 0.59
HDAC10 Q969S8 1/20 0.59
HDAC11 Q96DB2 1/20 0.59
HDAC8 Q9BY41 1/20 0.59
HDAC6 Q9UBN7 1/20 0.59
HDAC9 Q9UKV0 1/20 0.59
HDAC5 Q9UQL6 1/20 0.59

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27615885 0.93 FFAR1 (0.80) FFAR1MAPTRXFP1SRD5A2FFAR4
SCHEMBL70972 0.88 FFAR1 (0.70) FFAR1MAPTRXFP1SRD5A2FFAR4
SCHEMBL10327442 0.87 MAPT (0.57) FFAR1MAPTRXFP1SRD5A2FFAR4
SCHEMBL27615872 0.87 FFAR1 (0.60) FFAR1MAPTRXFP1SRD5A2FFAR4
SCHEMBL9094542 0.87 FFAR1 (0.65) FFAR1MAPTRXFP1SRD5A2FFAR4
SCHEMBL2774842 0.86 FFAR1 (1.00) FFAR1SRD5A2FFAR4PLAAT3PLAAT5
SCHEMBL19322275 0.86 DPP4 (0.63) FFAR1MAPTRXFP1SRD5A2FFAR4
Diphenylether SCHEMBL30565429 0.86 FFAR1 (0.66) FFAR1MAPTRXFP1SRD5A2FFAR4
SCHEMBL19322269 0.86 FFAR1 (0.60) FFAR1SRD5A2FFAR4PLAAT3PLAAT5
SCHEMBL19322285 0.86 FFAR1 (0.60) FFAR1SRD5A2FFAR4PLAAT3PLAAT5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10654880-B2 Methods for preparation of glycosphingolipids and uses thereof LIANG PI HUI (TW) 2020-05-19 US disclosed
US-10654880-B2 Methods for preparation of glycosphingolipids and uses thereof LIANG PI HUI (TW) 2020-05-19 US disclosed
EP-2661440-B1 METHOD FOR THE PREPARATION OF GLYCOSPHINGOLIPIDS UNIV NAT TAIWAN (TW) 2017-09-27 EP disclosed
EP-2661440-B1 METHOD FOR THE PREPARATION OF GLYCOSPHINGOLIPIDS UNIV NAT TAIWAN (TW) 2017-09-27 EP disclosed
US-20160229881-A1 METHODS FOR PREPARATION OF GLYCOSPHINGOLIPIDS AND USES THEREOF LIANG PI-HUI (TW) 2016-08-11 US disclosed
US-20160229881-A1 METHODS FOR PREPARATION OF GLYCOSPHINGOLIPIDS AND USES THEREOF LIANG PI-HUI (TW) 2016-08-11 US disclosed
US-20160229881-A1 METHODS FOR PREPARATION OF GLYCOSPHINGOLIPIDS AND USES THEREOF LIANG PI-HUI (TW) 2016-08-11 US disclosed
US-9181292-B2 Methods for preparation of glycosphingolipids and uses thereof LIANG PI-HUI (TW) 2015-11-10 US disclosed
US-9181292-B2 Methods for preparation of glycosphingolipids and uses thereof LIANG PI-HUI (TW) 2015-11-10 US disclosed
US-9181292-B2 Methods for preparation of glycosphingolipids and uses thereof LIANG PI-HUI (TW) 2015-11-10 US disclosed
EP-2661440-A2 METHODS FOR PREPARATION OF GLYCOSPHINGOLIPIDS AND USES THEREOF National Taiwan University (TW) 2013-11-13 EP disclosed
US-20120178705-A1 METHODS FOR PREPARATION OF GLYCOSPHINGOLIPIDS AND USES THEREOF NATIONAL TAIWAN UNIVERSITY (TW) 2012-07-12 US disclosed
US-20120178705-A1 METHODS FOR PREPARATION OF GLYCOSPHINGOLIPIDS AND USES THEREOF NATIONAL TAIWAN UNIVERSITY (TW) 2012-07-12 US disclosed
US-20120178705-A1 METHODS FOR PREPARATION OF GLYCOSPHINGOLIPIDS AND USES THEREOF NATIONAL TAIWAN UNIVERSITY (TW) 2012-07-12 US disclosed
WO-2012094540-A2 METHODS FOR PREPARATION OF GLYCOSPHINGOLIPIDS AND USES THEREOF NATIONAL TAIWAN UNIVERSITY (TW) 2012-07-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120178705-A1 METHODS FOR PREPARATION OF GLYCOSPHINGOLIPIDS AND USES THEREOF UGCG, CERS2, SGMS1 FFAR1 812/4885MAPT 2929/4885RXFP1 4469/4885
US-20160229881-A1 METHODS FOR PREPARATION OF GLYCOSPHINGOLIPIDS AND USES THEREOF UGCG, CERS2, SGMS1 FFAR1 812/4885MAPT 2929/4885RXFP1 4469/4885
US-10654880-B2 Methods for preparation of glycosphingolipids and uses thereof UGCG, CERS2, SGMS1 FFAR1 812/4885MAPT 2929/4885RXFP1 4469/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.